Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Apr 3;32(4):861-862.
doi: 10.1016/j.ymthe.2024.03.019. Epub 2024 Mar 19.

CARs come to AID

Francis Ayuk  1 , Boris Fehse  2
Affiliations
Editorial

CARs come to AID

Francis Ayuk et al. Mol Ther. .
No abstract available

PubMed Disclaimer

References

    1. Müller F., Taubmann J., Bucci L., Wilhelm A., Bergmann C., Völkl S., Aigner M., Rothe T., Minopoulou I., Tur C., et al. CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up. N. Engl. J. Med. 2024;390:687–700. doi: 10.1056/NEJMoa2308917. - DOI - PubMed
    1. Granit V., Benatar M., Kurtoglu M., Miljković M.D., Chahin N., Sahagian G., Feinberg M.H., Slansky A., Vu T., Jewell C.M., et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study. Lancet Neurol. 2023;22:578–590. doi: 10.1016/S1474-4422(23)00194-1. - DOI - PMC - PubMed
    1. Haghikia A., Hegelmaier T., Wolleschak D., Böttcher M., Desel C., Borie D., Motte J., Schett G., Schroers R., Gold R., Mougiakakos D. Anti-CD19 CAR T cells for refractory myasthenia gravis. Lancet Neurol. 2023;22:1104–1105. doi: 10.1016/S1474-4422(23)00375-7. - DOI - PubMed
    1. Fischbach F., Richter J., Pfeffer L.K., Fehse B., Berger S.C., Reinhardt S., Kuhle J., Badbaran A., Rathje K., Gagelmann N., et al. CD19 directed chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med. 2024 doi: 10.1016/j.medj.2024.03.002. in press. - DOI - PubMed
    1. Berger S.C., Fehse B., Akyüz N., Geffken M., Wolschke C., Janson D., Gagelmann N., Luther M., Wichmann D., Frenzel C., et al. Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor T cell therapy. Haematologica. 2023;108:444–456. doi: 10.3324/haematol.2022.281110. - DOI - PMC - PubMed

Publication types

LinkOut - more resources